RESULTS FROM TWO PHASE 3 RANDOMIZED TRIALS OF ENOBOSARM, SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM), FOR THE PREVENTION AND TREATMENT OF MUSCLE WASTING IN NSCLC.
Publication
, Conference
Crawford, J; Prado, CMM; Hancock, ML; Johnston, MA; Dalton, JT; Steiner, MS
Published in: JOURNAL OF THORACIC ONCOLOGY
November 1, 2013
Duke Scholars
Published In
JOURNAL OF THORACIC ONCOLOGY
EISSN
1556-1380
ISSN
1556-0864
Publication Date
November 1, 2013
Volume
8
Start / End Page
S1199 / S1199
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Crawford, J., Prado, C. M. M., Hancock, M. L., Johnston, M. A., Dalton, J. T., & Steiner, M. S. (2013). RESULTS FROM TWO PHASE 3 RANDOMIZED TRIALS OF ENOBOSARM, SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM), FOR THE PREVENTION AND TREATMENT OF MUSCLE WASTING IN NSCLC. In JOURNAL OF THORACIC ONCOLOGY (Vol. 8, pp. S1199–S1199). LIPPINCOTT WILLIAMS & WILKINS.
Crawford, Jeffrey, Carla M. M. Prado, Michael L. Hancock, Mary A. Johnston, James T. Dalton, and Mitchell S. Steiner. “RESULTS FROM TWO PHASE 3 RANDOMIZED TRIALS OF ENOBOSARM, SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM), FOR THE PREVENTION AND TREATMENT OF MUSCLE WASTING IN NSCLC.” In JOURNAL OF THORACIC ONCOLOGY, 8:S1199–S1199. LIPPINCOTT WILLIAMS & WILKINS, 2013.
Crawford J, Prado CMM, Hancock ML, Johnston MA, Dalton JT, Steiner MS. RESULTS FROM TWO PHASE 3 RANDOMIZED TRIALS OF ENOBOSARM, SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM), FOR THE PREVENTION AND TREATMENT OF MUSCLE WASTING IN NSCLC. In: JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS; 2013. p. S1199–S1199.
Crawford, Jeffrey, et al. “RESULTS FROM TWO PHASE 3 RANDOMIZED TRIALS OF ENOBOSARM, SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM), FOR THE PREVENTION AND TREATMENT OF MUSCLE WASTING IN NSCLC.” JOURNAL OF THORACIC ONCOLOGY, vol. 8, LIPPINCOTT WILLIAMS & WILKINS, 2013, pp. S1199–S1199.
Crawford J, Prado CMM, Hancock ML, Johnston MA, Dalton JT, Steiner MS. RESULTS FROM TWO PHASE 3 RANDOMIZED TRIALS OF ENOBOSARM, SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM), FOR THE PREVENTION AND TREATMENT OF MUSCLE WASTING IN NSCLC. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS; 2013. p. S1199–S1199.
Published In
JOURNAL OF THORACIC ONCOLOGY
EISSN
1556-1380
ISSN
1556-0864
Publication Date
November 1, 2013
Volume
8
Start / End Page
S1199 / S1199
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology